Seeing is believing: Stem cell therapy – KTVA
KTVA |
Seeing is believing: Stem cell therapy
KTVA Seeing is believing: Stem cell therapy. Sunday, April 8th 2018, 11:16 pm AKDT by Ivanhoe Newswire. Updated: Monday, April 9th 2018, 4:01 pm AKDT. MIAMI, Fla. (Ivanhoe Newswire) — It’s estimated that nearly 1.3 Americans are legally blind. Now a doctor … |
KTVA |
Seeing is believing: Stem cell therapy
KTVA Seeing is believing: Stem cell therapy. Sunday, April 8th 2018, 11:16 pm AKDT by Ivanhoe Newswire. Updated: Monday, April 9th 2018, 4:01 pm AKDT. MIAMI, Fla. (Ivanhoe Newswire) — It’s estimated that nearly 1.3 Americans are legally blind. Now a doctor … |
Colorado College News |
Qiu Chang Wu ’18 Named NSF Graduate Research Fellow
Colorado College News Qiu Chang Wu ’18 has been awarded a National Science Foundation Graduate Research Fellowship, one of two Colorado College seniors to receive the highly competitive fellowship this year. The award will support Wu’s research interests in systems and … |
Massive |
A new study shows that some are ‘immune’ to CRISPR. What does it mean for biology’s breakthrough editor?
Massive Even for those Cas9 proteins from humans, we can probably find ways to decrease their chance that they are recognized by the immune system, even though this is yet to be done. To take things further, not all CRISPR systems found in bacteria use Cas9 to … |
Massive |
A new study shows that some are ‘immune’ to CRISPR. What does it mean for biology’s breakthrough editor?
Massive Even for those Cas9 proteins from humans, we can probably find ways to decrease their chance that they are recognized by the immune system, even though this is yet to be done. To take things further, not all CRISPR systems found in bacteria use Cas9 to … |
|
Immunotherapy for Triple-Negative Breast Cancer
OncLive What happens is with immunotherapy for breast cancer, because it’s not a very immunogenic disease, it’s really important to do it early. We saw a doubling or tripling of pathologic complete response rates in the neoadjuvant I-SPY trial. In the first … |